Scheduled Awakenings for the Treatment of Nocturnal Enuresis

Not Applicable

Completed

• Conditions: Nocturnal Enuresis
• Interventions: Device: Lully Sleep Guardian

• Registration Number: NCT03047720
• Lead Sponsor: Indiana University

Brief Summary

This study is a simple effectiveness trial to determine if the Lully Sleep Guardian has any effect on benign nocturnal enuresis.

Detailed Description

Primary monosymptomatic nocturnal enuresis (PMNE) is defined by the Diagnostic \& Statistical Manual of Mental Disorders (DSM- IV) as an involuntary voiding of urine during sleep, with a severity of at least twice a week, in children aged \>5 years in the absence of congenital or acquired defects of the central nervous system(1-3).

PMNE affects 10-20% kids at 5 years old (1, 4, 5). It does resolve spontaneously so that 5% of 10 year olds and 1% of 15 year olds are still affected (2-4). Is more common in boys. While the disease its self is benign, and improves without intervention, it does pose a significant social and emotional burden on the child and their family. These include parental disapproval, sibling teasing, and inability to attend sleep overs with peers, all of which lead to families seeking treatment options (3, 4).

Current treatments start with conservative management. This includes appropriate fluid intake, scheduled toileting during the day, avoidance of bladder irritants and constipation (4, 5). If these fail to improve symptoms or families are looking for a more active form of treatment, first line therapy is either a bed wetting alarms or desmopressin (1, 4, 5).

The Lully Sleep Guardian was initially developed for use in night terrors. The device works by programing a vibrating disk that is placed under the child's bed to alter sleep patterns and prevent the onset of sleep terrors. The child is not woken up for the treatment of sleep terrors. The device has also been shown to anecdotally improve users' nocturnal enuresis. There have been no reports of safety concerns or hazards with the device (7, 8).

The aim of this study is to determine the effectiveness of scheduled awakenings, with the Lully Sleep Guardian, in patients with PMNE, at reducing the frequency of bed-wetting.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2016-11-04
• Study First Submitted: 2016-12-28
• Study First Submitted QC: 2017-02-06
• Study First Posted: 2017-02-09
• Primary Completion: 2018-08-07
• Study Completion: 2018-08-07
• Results First Submitted: 2020-07-07
• Results First Submitted QC: 2020-09-24
• Status Verified: 2020-10
• Results First Posted: 2020-10-19
• Last Update Submitted: 2020-10-26
• Last Update Posted: 2020-11-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Benign nocturnal enuresis
• Age: 5 - 17
• Must have or have access to an Apple iPhone, iPad, or iPod Touch

Read More

Exclusion Criteria

• Diurnal Enuresis
• Constipation
• Neurogenic Bladder
• Any serious underlying cardiopulmonary problems that require diuretics or antihypertensive medications to manage
• Any bladder active medications
• Age: < 5 years of age; > 17 years of age
• Cerebral Palsy
• Mental disorders, mood disorders, or autism-spectrum disorder
• Epilepsy or seizure history
• Restless leg syndrome
• Use of benzodiazepine/clonidine

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
One: Study Phases (S1 and S2)	Lully Sleep Guardian	The therapeutic phase of this study for the participant in Arm One will be: 6 weeks of behavioral modifications plus the Lully device (S1), followed by 6 weeks of behavioral modifications only without the device (S2)
Two: Study Phases (S2 and S1)	Lully Sleep Guardian	The therapeutic phase of this study for the participant in Arm Two will be: 6 weeks of behavioral modifications only without the device (S2), followed by 6 weeks of behavioral modifications plus use of the Lully device(S1)

Primary Outcome Measures

Name	Time	Method
Change in Number of Dry Nights When Using the Scheduled Awakening Protocol With the Lully Sleep Guardian	baseline and 6 weeks (end of S1)	Participants were asked to enter responses daily into a Lully Study app.The questions the participant was prompted to answer: Did your child have a bed wetting episode last night? Answered by yes or no.
Change in Number of Voids Per Night When Using the Scheduled Awakening Protocol With the Lully Sleep Guardian	Not measured.	Participants were asked to enter responses daily into a Lully Study app.The questions the participant was prompted to answer: Did your child have a bed wetting episode last night? (Answered by yes or no) What time?
QOL Measures Using the KIDS Screen Questionnaire at 10 Weeks	10 weeks	Participants were asked to complete QOL survey (KIDSCREEN 27) at baseline, before starting therapeutic phase, and after completing therapeutic phase. KIDSCREEN is a standardized questionnaire for children and adolescents to assess their health related quality of life (HRQoL). Each items scored on a 5-point scale. There is the KIDSCREEN 54 (long version) KIDSCREEN 27 (short version) KIDSCREEN 10 Index. For analysis, decision made to analyze questions in the KIDSCREEN 10 Index questions only. For KIDSCREEN 10, it is a 5 point Likert Scale with a score range of 10 to 50 with higher scores indicating better quality of life.
Change in Quantity of Wetness When Bedwetting Occurred While Using the Scheduled Awakening Protocol With the Lully	Not measured.	Participants were asked to enter responses daily into a Lully Study app. In a free text box the family was asked to add additional information to describe how wet the child was using the following 1-5 scale: 1- wet underwear; 2-wet underwear and damp pajamas; 3- soaked underwear, pajamas; 4-soaked pajamas, damp mattress; 5- soaked mattress.

Trial Locations

Locations (1)

Riley Hopspital for Children; 🇺🇸 Indianapolis, Indiana, United States